Magnesium sulfate neuroprotection in preterm infants

Evaluation of neuroprotective effects of magnesium sulfate on preterm infants with a gestational age of 32-36 weeks

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120826010664N5

Enrollment

246

Registered

2019-12-26

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant immaturity. Preterm [premature] newborn [other]

Interventions

Intervention 1: Intervention group: One time Intravenous infusion of Magnesium sulfate (made in pasteur institute co, Tehran, Iran) 50% diluted in Ringer lactate serum at a dose of 2 g per hour for 12

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Singleton pregnancy Spontaneous labor Gestational age between 32 and 36 weeks

Exclusion criteria

Exclusion criteria: Maternal underlying diseases Fetal abnormalities Intrauterine growth retardation (IUGR) Contraindications for use of magnesium sulfate Iatrogenic preterm birth

Design outcomes

Primary

Measure	Time frame
Neurodevelopmental status of infants (including APGAR score, Arterial blood pH after the birth, and Neurodevelopment status after the age of 4 months). Timepoint: 0, 4, 6, 8, 10, and 12 months after the birth. Method of measurement: Blood test and standard Ages & Stages Questionnaires (ASQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Saeideh Zndi

Tehran University of Medical Sciences

s.zandi2020@gmail.com+98 21 7788 3288

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026